VJOncology is committed to improving our service to you

ESMO 2019 | OpACIn-neo trial RFS and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma

VJOncology is committed to improving our service to you

Georgina Long

Georgina Long, MD, PhD, FRACP, from the University of Sydney, Sydney, Australia, explains the 18-month relapse-free survival and biomarker analyses from the OpACIN-neo trial (NCT02977052). This trial aims to identify the optimal dosing schedule of neoadjuvant ipilimumab and nivolumab in stage III melanoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter